iPSC-GLP1R-KO-H4
KAUSTi011-B
General
Cell Line |
|
| hPSCreg name | KAUSTi011-B |
| Cite as: | KAUSTi011-B (RRID:CVCL_A1WH) |
| Alternative name(s) |
iPSC-GLP1R-KO-H4
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
|
| Last update | 1st November 2020 |
| User feedback | |
Provider |
|
| Generator | King Abdullah University of Science and Technology (KAUST) |
| Owner | King Abdullah University of Science and Technology (KAUST) |
| Distributors | |
| Derivation country | Saudi Arabia |
External Databases |
|
| BioSamples | SAMEA7679542 |
| Cellosaurus | CVCL_A1WH |
| Wikidata | Q105509755 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 1-4 |
| Ethnicity | Saudi |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA7679541 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information | Dr. Fowzan S. Alkuraya: faikuraya@kfshrc.edu.sa / King Faisal Specialist Hospital and Research Centre |
| Alternatives to consent are available? | No |
| Has the donor agreed to be re-contacted? | Unknown |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | No |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Patient Fibroblasts PT-15DG1507 was obtained from King Faisal Specialist Hospital and Research Center |
| Approval number | RCGEN/342/40 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | KAUST Institutional Biosafety and Bioethics Committee |
| Approval number | 17IBEC14 |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Stemgent |
hIPSC Derivation
General |
|
| Source cell line name |
Pt-15DG1507 Derived from same source line (potentially other lot and donor, see below):
|
| Source cell type | |
| Age of donor (at collection) | 1-4 |
| Passage number reprogrammed | 4 |
Reprogramming method |
|
| Vector type | None |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
mRNA, Small molecules, miRNA
|
| mRNA | |
| Small molecules |
|
Other |
|
| Selection criteria for clones | The emerging embryonic stem cell-like colonies were identified by distinct borders, bright centers, tight-packed cells and high nucleus to cytoplasm ratio |
| Derived under xeno-free conditions |
Yes |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
TrypLE
|
| O2 Concentration | 5 % |
| CO2 Concentration | 5 % |
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| SOX2 |
Yes |
|
|
|||
| NANOG |
Yes |
|
|
|||
| SSEA-4 |
Yes |
|
Morphology pictures
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.